Qteris, Inc.

skin and skin structure infections (sssi) colonized by methicillin-resistant staphylococcus aureus (mrsa) present an escalating risk in the developed and developing world. in 2005, mrsa was blamed as the leading cause of death by an infectious agent in the united states. apart from resistance, other issues exist with the antibiotic treatment of mrsa-colonized sssi, including limited efficacy, renal and liver toxicity associated with antimicrobial therapy, and destruction of beneficial microflora. recently, the use of magnetic nanoparticle-enhanced radio frequency ablation has demonstrated encouraging results in the treatment of various cancers, with several companies undergoing clinical trials for glioblastoma, prostate carcinoma, and breast carcinoma. utilizing a targeted delivery of heat to pathogen cells, qteris' technology is designed to act as an adjuvant to standard-of-care antibiotic treatment for the treatment of sssis.